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Abstract: PURPOSE Children with Down syndrome (constitutive trisomy 21) that develop acute lym-
phoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled
with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblas-
tic leukemia (B-ALL). This highlights the lack of suitable treatment for Down syndrome children with
B-ALL. EXPERIMENTAL DESIGN To facilitate the translation of new therapeutic agents into clinical
trials, we built the first preclinical cohort of patient-derived xenograft (PDX) models of DS-ALL, com-
prehensively characterized at the genetic and transcriptomic levels, and have proven its suitability for
preclinical studies by assessing the efficacy of drug combination between the MEK inhibitor trametinib
and conventional chemotherapy agents. RESULTS Whole-exome and RNA-sequencing experiments re-
vealed a high incidence of somatic alterations leading to RAS/MAPK pathway activation in our cohort of
DS-ALL, as well as in other pediatric B-ALL presenting somatic gain of the chromosome 21 (B-ALL+21).
In murine and human B-cell precursors, activated KRASG12D functionally cooperates with trisomy 21
to deregulate transcriptional networks that promote increased proliferation and self renewal, as well as
B-cell differentiation blockade. Moreover, we revealed that inhibition of RAS/MAPK pathway activation
using the MEK1/2 inhibitor trametinib decreased leukemia burden in several PDX models of B-ALL+21,
and enhanced survival of DS-ALL PDX in combination with conventional chemotherapy agents such as
vincristine. CONCLUSIONS Altogether, using novel and suitable PDX models, this study indicates
that RAS/MAPK pathway inhibition represents a promising strategy to improve the outcome of Down
syndrome children with B-cell precursor leukemia.
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Relevance 
B-cell precursor Acute Lymphoblastic Leukemia (B-ALL) is the most common type of 
childhood malignancies, accounting for more than 20% of all pediatric cancers 
worldwide. Although survival rates have significantly improved, many children with B-
ALL continue to have a poor prognosis, and suffer from treatment related toxicity and 
relapse; clinical features that are exemplified in Down syndrome children with acute 
lymphoblastic leukemia (known as DS-ALL). Among the most frequent somatic 
alterations seen in childhood B-ALL, gain of chromosome 21 (+21) and RAS/MAPK 
alterations are found in 30-40% and 50%, respectively. In this study, using DS-ALL as a 
paradigm, we showed that both events functionally cooperate and that treatment with the 
MEK inhibitor Trametinib improved the survival in patient-derived xenograft models of 
childhood B-ALL+21 with RAS activating mutations. The comprehensive repository of 
preclinical models developed here is of general relevance to investigate new targeted 




Children with Down syndrome (DS, constitutive trisomy 21) that develop acute 
lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-
related mortality coupled with a higher cumulative incidence of relapse, compared to 
other children with B-cell acute lymphoblastic leukemia (B-ALL). This highlights the 
lack of suitable treatment for DS children with B-ALL.  
Experimental design: 
To facilitate the translation of new therapeutic agents into clinical trials, we built the first 
preclinical cohort of patient-derived xenograft (PDX) models of DS-ALL, 
comprehensively characterized at the genetic and transcriptomic levels, and have proven 
its suitability for preclinical studies by assessing the efficacy of drug combination 
between the MEK inhibitor Trametinib and conventional chemotherapy agents. 
Results: 
Whole exome and RNA-sequencing experiments revealed a high incidence of somatic 
alterations leading to RAS/MAPK pathway activation in our cohort of DS-ALL, as well 
as in other pediatric B-ALL presenting somatic gain of the chromosome 21 (B-ALL+21). 
In murine and human B cell precursors, activated KRAS
G12D
 functionally cooperates with 
trisomy 21 to deregulate transcriptional networks that promote increased proliferation and 
self-renewal, as well as B-cell differentiation blockade. Moreover, we revealed that 
inhibition of RAS/MAPK pathway activation using the MEK1/2 inhibitor Trametinib 
decreased leukemia burden in several PDX models of B-ALL+21, and enhanced survival 
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of DS-ALL PDX in combination with conventional chemotherapy agents such as 
vincristine.  
Conclusions: 
Altogether, using novel and suitable PDX models, this study indicates that RAS/MAPK 
pathway inhibition represents a promising strategy to improve the outcome of DS 




B-cell precursor Acute Lymphoblastic Leukemia (B-ALL) is the most common type of 
childhood malignancy. Children with Down syndrome (DS) face a 27-fold increased risk 
to develop B-ALL (known as DS-ALL) (1), associated with a worse outcome and a 
significantly lower Event-free survival (EFS: 64% vs 81%) and overall survival rate (OS: 
74% vs 89%) compared to other children (2). Treatment intensification is limited in DS-
ALL due to a higher therapy-related morbidity (TRM) (7% vs 2%), ultimately leading to 
a higher rate of relapses (26% versus 15%) (2, 3). This emphasizes the need to better 
understand the mechanisms driving leukemia in DS-ALL, so that novel and more targeted 
treatments can be developed for these children. 
 
At the genetic level, apart from the constitutive trisomy 21, DS-ALL presents a normal 
karyotype in more than 40% of cases, and a lower incidence of ETV6-RUNX1 or High 
Hyperdiploid (HeH) karyotypes (2, 4). Half of DS-ALL samples overexpress cytokine 
receptor-like factor 2 (CRLF2) either through microdeletions on chromosome X (P2RY8-
CRLF2 fusion) or translocations to the IGH locus (5-7). JAK2 activating mutations, 
affecting the Arginine R683 residue located in the pseudokinase domain, are also more 
frequently found in DS-ALL than in any other subgroups of pediatric B-ALL (8, 9), 
suggesting an oncogenic cooperation between cytokine signaling activation and 
constitutive trisomy 21. Other genetic alterations affecting NRAS, KRAS, IKZF1, PAX5 or 
CDKN2A/B genes are commonly found in DS- and non-DS B-ALL (10, 11). 
The development of DS-ALL models, from the transgenic Ts1Rhr mice (trisomic for the 
Down Syndrome Critical Region (DSCR)) (12), has highlighted the complexity of DS-
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ALL leukemogenesis in vivo (13). Indeed, four additional alterations affecting CRLF2, 
JAK2, IKZF1 and PAX5 genes, added to trisomy 21, were required to drive a B-ALL 
phenotype in this model. Moreover, the lack of cellular models of DS-ALL precludes the 
development of simple screening assays to identify novel therapeutic approaches. 
 
In non-DS pediatric B-ALL, complete or partial gain of chromosome 21 (+21) is seen in 
30-40% of cases. More than 90% of HeH-ALL are tetrasomic for the whole chromosome 
21; some HeH cases harbor three additional copies of this chromosome (14). 
Intrachromosomal amplification of chromosome 21 (a.k.a. iAMP21) is a high-risk 
cytogenetic abnormality in pediatric B-ALL and is characterized by a pattern of 
deleted/amplified regions of the chromosome 21, with the aberration on chromosome 21 
considered to be the initiating event (15). Trisomy 21 has also been reported in 15% of 
ETV6-RUNX1 B-ALL (16). Interestingly, the minimal region of amplification on 
chromosome 21, found in both HeH and iAMP21 B-ALL overlap with the DSCR (14, 
15). This strongly suggests that the increased dosage of specific genes located in this 
DSCR region plays a central role in B cell leukemogenesis, irrespective of whether it 
results from a constitutive (DS) or somatic (HeH or iAMP21) chromosomal abnormality. 
Among them, trisomy of Hmgn1 (encoding the High mobility group nucleosomal binding 
protein 1) has been shown to suppress the Histone H3 tri-methylation of Lys27 
(H3K27me3) repressive mark and induce global transcriptional amplification to promote 
B-cell proliferation and B cell precursor phenotypes (13, 17). Moreover, the DYRK1A 
(Dual specificity tyrosine-phosphorylation-regulated kinase 1A) regulates B cell 
proliferation and differentiation (18), and increased dosage of Dyrk1a predisposes to DS-
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leukemia (19). Together, these results highlight that at least 2 genes within the DSCR 
promote B cell leukemia. However, the molecular bases of oncogenic cooperation 
between constitutive trisomy 21 and the somatic alterations found in DS-ALL remain 
largely unknown. 
 
In this study, we showed that trisomy 21 functionally cooperates with constitutive 
activation of RAS/MAPK pathway in murine and human B-cell precursors, indicating 
that disrupting this mechanism may have a therapeutic impact for DS children with B-cell 
leukemia. We built a comprehensive and preclinical cohort of patient-derived xenograft 
(PDX) models, and show efficacy of MEK1/2 inhibition on human B-ALL samples 
harboring NRAS, KRAS, JAK2 and CBL mutations. Altogether, these results indicated that 
the RAS/MAPK inhibitor Trametinib is therapeutically exploitable to improve the 
outcome of DS children with B-ALL when combined with conventional chemotherapy 
agents.  
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Material and Methods 
Human samples and sequencing  
Human peripheral blood (PB) and bone marrow (BM) samples were collected from 
Trousseau, Necker, Tours and Toulouse hospitals (France), and Perth Children`s Hospital 
(Australia). Nine samples were provided under the MAPPYACTS protocol (clinical 
trial.gov: NCT02613962). All human samples were obtained with the written or signed 
consent of the patient or parents/guardians. This study conforms to the provisions of the 
Declaration of Helsinki, was approved by independent ethics committees and complied to 
institutional, local and national regulations. 
Cells were subjected to Ficoll gradient and then either used fresh or frozen in FBS with 
10% DMSO. DNA and RNA were extracted using RNA/DNA/Protein Purification Plus 
kit (Norgen).  WES libraries were prepared using SureSelect All Exon V5 Clinical 
Research Exome V1 or CREV2 kits (Agilent). Sequencing was performed on a 
HiSeq2000 (Illumina) with a median depth of 100X. Detection of SNVs and small indels 
were done using Varscan 2.3.7 (20). RNAseq libraries were prepared using SureSelect 
Automated Strand Specific RNA Library Preparation kit and sequenced to obtain at least 
100M reads. Quality control was performed using FastQC (v0.11.7, Babraham Institute) 
and quantification of transcript expression was performed with Salmon software 
(v0.11.2)(21). The differential gene expression analysis was performed using R (v3.4.0) 




Ts1Rhr mice have been previously described (12). 6-8 weeks old Ts1Rhr and wild-type 
controls bone marrow (BM) cells, after red cells lysis, were cultivated overnight in 
IMDM medium supplemented with 20% FBS, penicillin (100U/mL)-streptomycin 
(100μg/mL), 2mM L-Glutamine, 1mM sodium pyruvate, 50nM 2-mercaptoethanol and 
recombinant murine IL7, SCF and FLT3-L at 10ng/mL. BM cells were spin-infected in 
culture media containing 5μg/mL polybrene and 7.5mM HEPES buffer as previously 
described, with retroviral particles produced from the murine stem cell virus (MSCV)-




respectively. After 24h, 8000 B220+cherry+ sorted cells were plated in M3630 and CFU-
preB colonies were scored every week. 
To generate the PDX, 0.1-2x10
6
 B-ALL cells from 30 patients (BM or PB) were injected 




/SzJ (NSG) mice by 
intrafemoral (i.f) injection. Subsequent NSG generations were injected with 0.1 to 1×10
6
 
cells per animal intravenous (i.v) or i.f. Luciferase expressing models were developed by 
transduction of B-ALL cells from primografts with lentiviral particles obtained from the 
FUW-Luc-mCherry-puro vector (a gift from A. L. Kung, Dana Faber Cancer Institute, 
Boston). Bioluminescence monitoring was performed on mice injected with 150mg/kg of 
D-Luciferin, imaged with IVIS50 or Ami HT system; Bioluminescence intensity was 
expressed as photons per second per surface (p/s/cm
2
 = ROI). 
Mice were maintained at the Gustave Roussy or Telethon Kids Institute preclinical 
facility and all experiments were approved by the French or Australian national animal 
care and use committee respectively. 
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Western blotting  
To assess the constitutive activation of signalling pathways, B-ALL cells harvested from 
PDX were starved for 5-6 hours prior to protein extraction, washed and centrifuged at 
1200 rpm for 5 min. Cell pellets were lysed in cold RIPA buffer (50mM Tris-HCL pH8, 
1mM EDTA, 150mM NaCl, 1% NP40, 0.1% SDS and 0.5% DOC) supplemented with 
1X Complete
TM 
(Roche), 50 mM NAF, 2mM PMSF and 1mM Na3VO4. Proteins were 
separated on a NuPAGE Bis-Tris polyacrylamide gel and transferred onto a nitrocellulose 
membrane (GE Healthcare). Antibodies were purchased from Cell signaling and 
SantaCruz (Methods - Table S8). Quantification of band intensities was estimated using 





 cells from PDX were plated in 100µL of RPMI 1640 medium 
supplemented with 10% FBS, penicillin (100U/mL)-streptomycin (100μg/mL), 2mM L-
glutamine, and human IL7, SCF and FLT3-L at 10ng/mL. Dexamethasone, Methotrexate, 
Vincristine sulfate, Selumetinib and Trametinib (all purchased from MedKoo) were 
diluted in DMSO. After 72h of incubation, MTT assays (absorbance 490nm) was 
performed by adding 20µL/well of CellTiter 96® AQueous One Solution Reagent 
(Promega).  




, or when 1% of 
human blasts where detected in the peripheral blood. NSG mice were then treated with 
Trametinib (1.5mg/kg, oral gavage 5 times per week) (23), vincristine sulfate (0.5mg/kg, 
intra-peritoneal injection once a week) (24), or both. Mice were monitored by 
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bioluminescence (IVIS Spectrum and Ami HT) and blood samplings. At sacrifice, flow 
cytometry analyses were used to determine the leukemic burden in the spleen and BM.  
 
Flow cytometry analyses 
For all flow cytometry experiments, cells were stained in PBS 1X supplemented with 2% 
FBS for 30 minutes at 4°C (Methods – Table S8). Analyses were performed with 
CANTO-II or CANTO-X instruments (BD), and data were analyzed using FlowJo 
software (version FlowJo 9.3.2). Murine B220+/mCherry positive cells and human B-
ALL blasts were sorted on ARIAIII, Fusion or INFLUX instruments (BD). 
 
Data availability 
Whole exome sequencing and RNAseq data from primary samples were deposited into 
EGA under the accession number EGAS00001003760. RNAseq data from CFU-preB 
experiments are available on EBI under the accession number E-MTAB-8005. 
 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism (version 6, GraphPad), unless 
otherwise mentioned. The log-rank test was used for survival analyses. For other 
experiments, statistical significance was evaluated using the Mann-Whitney U test or the 





Genetic and transcriptomic landscapes of the B-ALL+21 cohort 
To investigate the mechanisms of oncogenic cooperation in pediatric B-ALL+21, we 
collected 8 DS-ALL, 8 iAMP21, 16 HeH and 12 primary patient samples from other 
subgroups of pediatric B-ALL (referred to as `Others`) (Supplementary Table S1), and 
performed Whole Exome Sequencing (WES) and RNA-sequencing experiments to 
comprehensively characterize the mutational landscape of this B-ALL cohort. We 
identified a total of 2067 non-synonymous SNVs or Indels (n=86.1±46 per sample) in 
coding regions, with an average of 3.6±4.1 acquired predicted driver mutations per 
sample as determined by Cancer Genome Interpreter (Supplementary Table S2) (25). The 
most common alterations affected genes encoding signaling effectors (NRAS, KRAS, 
FLT3, JAK2, CRLF2, SH2B3 and CBL n=27/44 samples), especially in B-ALL+21 as 
confirmed independently in publicly available pediatric B-ALL cohorts (Supplemental 
Figure 1A), followed by somatic alterations of transcription factors (n=15), chromatin 
modifiers (n=12), and cell cycle regulators (n=11) (Figure 1, Supplementary Tables S2 
and S3). 
Next, we used RNA-sequencing to identify fusion transcripts in our cohort applying 
stringent selection criteria in which fusion transcripts must be detected in at least two 
different algorithms (including deFuse, CRAC, TopHat and TopHat Fusion, 
Supplementary Table S4). We detected ETV6-RUNX1 fusions in two samples from the 
`Others` group (Others02 and Others03) and two novel `in-frame` transcripts fusing 
HM13 (Histocompatibility Minor 13) to REM1 (RRAD and GEM-like GTPase1) in the 
Others08 sample, and COPS3 to ACAD10 (Acyl-CoA Dehydrogenase Family Member 
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10) in iAMP02 (Supplementary Figure S1B, C). COPS3, also found to be mutated in 
Others01, encodes the COP9 signalosome subunit 3, known to mediate the stability of 
TP53, JUN and SOS1 (26). An `out-of-frame` transcript PAX5-CTNND2, associated 
with the ectopic expression of Catenin Delta 2, was identified in the DS01 sample 
(Supplementary Figure S1D). RNA-seq experiments also detected the overexpression of 
CRLF2 in DS02, DS03 and DS010 samples, confirming data obtained by Multiplex 
ligation-dependent probe amplification (MLPA) and/or flow cytometry analyses. 
 
Together, we detailed the mutational landscape of a cohort of 32 pediatric B-
ALL+21 samples, representative of the genetic alterations commonly found in DS-ALL, 
iAMP21 and HeH, and highlighting a potential oncogenic cooperation between gain of 




 cooperates with +21 in murine and human samples 
To better understand the molecular bases of this oncogenic cooperation, we first 
overexpressed KRAS
G12D 
in murine bone marrow cells harvested from 6-8 weeks old 
wild-type (WT) or partially trisomic (Ts1Rhr) mice. In methylcellulose assays, ectopic 
expression of KRAS
G12D
 increased the number and size of CFU-preB colonies in both 
WT and Ts1Rhr backgrounds (Figures 2A and B). KRAS
G12D
 expression in Ts1Rhr B 
cell precursors also enhanced their self-renewal capacity, as shown by serial replating 
experiments (Figure 2A). Similar observations were obtained using the mutant NRAS
G12D
 





pre-B colonies and maintained in liquid cultures, Ts1Rhr-KRAS
G12D
 cells have a higher 
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level of constitutive Erk1/2 phosphorylation in starved conditions (Figure 2C). 
Phenotypic analyses of the CFU colonies obtained at passage 1 (P1) revealed that 
KRAS
G12D 
expression, in wild-type or Ts1Rhr backgrounds, decreased the proportions of 
pre-pro-B (B220+CD19-Kit+), pre-B (B220+CD19+CD25+) and immature B cells 
(B220+CD19+IgM+), in favor of pro-B cells (CD43+B220+CD19+) (Supplementary 
Figure S2C). 
We performed RNA sequencing experiments on WT and Ts1Rhr B220+/CD19+/CD25- 
B cells harvested at P1, either expressing KRAS
G12D
 or not. Compared to WT controls, 
2039 genes were significantly deregulated in Ts1Rhr, 8361 genes in KRAS
G12D
, and 8967 
genes in Ts1Rhr-KRAS
G12D
 (p<0.05) (Supplementary Table S5). Genes encoding surface 
markers such as Kit (-5.6 fold) and Cd25 (Il2ra, -1.9 fold), or transcription factors known 





 compared to disomic (WT) or trisomic (Ts1Rhr) 
controls (Supplementary Figure S2C). To identify the transcriptional signatures 
associated with this oncogenic cooperation, we compared the differentially expressed 
genes between the paired conditions Ts1Rhr and WT, KRAS
G12D
 and WT, Ts1Rhr-
KRAS
G12D




 (Supplementary Table S5 
and Figure S2D). 261 genes were found commonly deregulated in these analyses (132 
upregulated and 129 downregulated genes) (Figure 2D), including the upregulation of 
DSCR genes, trisomic in the Ts1Rhr model (such as Erg, Wrb, Igsf5 and Psmg1), and the 
repression of several Immunoglobulin kappa (Igk) genes, indicative of a differentiation 
arrest at the pre-B stage. 
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Gene Set Enrichment Analyses (GSEA) confirmed that the genes located in the DSCR, 
were enriched in Ts1Rhr and in Ts1Rhr-KRAS
G12D
 compared to their disomic 
counterparts, as previously described (Supplementary Figure S2E) (13). Using the 
MSigDB c2 database, GSEA confirmed the enrichment of RAS/MAPK activation 
datasets, along with APC, MYC, TGFB1 and HDAC targets in wild-type or trisomic cells 
expressing the mutant KRAS
G12D





 paired comparison in line with previous observations (13). Positive 
enrichments in transcriptional signatures associated with early hematopoietic stem cells 
and progenitors were found in both Ts1Rhr and Ts1Rhr-KRAS
G12D
 context. Moreover, 
mature hematopoietic cells and B cell differentiation associated genes sets were 




(Figure 2E, Supplementary Figure 
S3, and Supplementary Table S6), indicative of an earlier B cell differentiation blockade 
of the Trisomic-KRAS
G12D 
B cell precursors. We also identified a Ts1Rhr-KRAS
G12D
 
specific signature of 1559 deregulated genes (788 down and 771 up) associated with the 
inhibition of cell cycle and B-cell differentiation, and with activation of stem cell and 
leukemia transcriptional programs (Supplemental Figure 3, Supplemental Table 5 and 6). 
To investigate the relevance of these transcriptional signatures in our datasets of human 
B-ALL, we first extracted the differentially expressed genes between the B-ALL+21 
samples harboring RAS activating mutations and B cell precursors CD34+CD38+CD19+ 
from healthy donors. 1814 genes were deregulated (p<0.05, Supplemental Table S7), 
including 238 upregulated and 43 downregulated genes in common with the Ts1Rhr-
KRAS
G12D 
vs WT comparison. This signature was significantly enriched in B-ALL+21 
with RAS mutations compared to other subtypes of B-ALL as shown by GSEA (Figure 
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2F and Supplementary Figures S4A, B). Among these commonly deregulated genes, 18 
genes were enriched in the trisomy 21/RAS mutated contexts in both human and murine 
sequencing datasets, including upregulation of LRRC32, USP36, LDLR and RFLNB, 
whose overexpression or function have been correlated with tumor development (Figures 
2G, H and Supplementary Table S7) (28-31) (and Human protein atlas available from 
www.proteinatlas.org). Moreover, a significant downregulation of IRF4, a key regulator 
of pre-B cell differentiation, was seen in Ts1Rhr-KRAS
G12D
 (-1.9 fold) and in B-
ALL+21/RAS mutated samples (-11.5 fold). Ectopic expression of IRF4 in Ts1Rhr-
KRAS
G12D
 cells resulted in growth inhibition and differentiation towards more CD25+ 
pre-B cells (Figure 2I-J, and supplemental Figure 4C), showing the functional relevance 
of low IRF4 level in leukemia maintenance. 
 
This combined analysis of murine models and human B-ALL demonstrated that 
constitutive RAS/MAPK activation functionally cooperates with gain of chromosome 21 
to enhance B cell precursors transformation, through the dysregulation of patient-relevant 
transcriptional signatures that control self-renewal, proliferation and B cell 
differentiation. 
 
Development of a comprehensive cohort of preclinical models for B-ALL+21 
To perform functional studies and assess the efficacy of new pharmacologic agents, we 
generated patient-derived xenograft (PDX) models. Four out of five DS-ALL samples 
successfully engrafted, as assessed by flow cytometry analyses from bone marrow and 
peripheral blood samples (Figures 3A-C and Supplementary Figure S5A). From these 
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primary PDXs, human DS-ALL blasts were transduced with lentiviral constructs 
encoding mCherry and Luciferase reporter genes, to follow disease progression and 
response to treatments through non-invasive in vivo imaging. Importantly, based on the 
expression of the surface markers CD19, CD34, CD38 and TSLPR (Thymic Stromal 
Lymphopoietin Protein Receptor, a.k.a. CRLF2), these in vivo models conserved the 
phenotypic architecture of the primary patient (Figures 3A-C and Supplementary Figure 
S5A). The reliability of these models was confirmed using RNA-sequencing, MLPA and 
targeted sequencing of the known driver mutations identified in the primary samples 
(Figure 3D and Supplementary Figures S5B-D). This approach was applied to an 
extended cohort of 23 B-ALL samples, leading to the successful development of 2 
iAMP21, 10 HeH and 5 Others PDX models (Supplemental Table S1). Importantly, the 
B-ALL+21/RAS mutated PDXs conserved the enrichment of transcriptional signature of 
281 genes described previously (Figure 3E), and presented a constitutive phosphorylation 
of the downstream effectors Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) 
compared to non-mutated B-ALL PDXs, although the intensity of P-ERK1/2 is variable 
between individual samples (Figure 3F and Supplementary Figure S5E). 
 
 In summary, we have developed a comprehensive cohort of 21 B-ALL PDX 
models, including 4 DS-ALL, providing new tools to better understand the mechanisms 
of oncogenic cooperation in human B-ALL and perform preclinical studies.  
 
Pharmacologic inhibition of MEK1/2 decreases leukemia burden in B-ALL+21 
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To assess the suitability of our murine and PDX models we developed, we tested the 
efficacy of MEK (Mitogen-Activated Protein Kinase (MAPK) kinases) inhibitors, which 
are essential downstream mediators of the RAS/MAPK pathway. First, the efficacy of the 
MEK1 inhibitor Selumetinib (AZD6244) (32) and the MEK1/2 inhibitor Trametinib 
(GSK1120212) (33) was tested on the Ts1Rhr-KRAS
G12D
 cells and on four human B-
ALL+21 samples freshly harvested from PDXs (Figures 4A, B and Supplementary 
Figures S6A-C). Both inhibitors significantly decreased cell viability and were associated 
with a dose-dependent decreased phosphorylation of the ERK1/2 in several models, with 
Trametinib treatment being up to 60-fold more cytotoxic than Selumetinib in human 
samples. Next, we investigated the efficacy of Trametinib on 9 additional B-ALL+21 (2 
iAMP21 and 7 HeH) and 5 `Others` samples (Figure 4C and Supplementary Figure S6C). 
All B-ALL subtypes responded to Trametinib with a significantly lower IC50 in DS-ALL 
(IC50= 0.04 µM) and HeH (IC50= 0.06 µM) samples compared to `Others` (IC50= 3.9 
µM), and was associated with an increased proportion of annexinV-positive cells (Figures 
4C and 4D, and Supplementary Figure S6D). In vivo, after 4 weeks of treatment with 
Trametinib (1.5mg/kg/day, oral gavage, 5 days a week), a decreased proportion of human 
CD45+ cells was observed in the bone marrow and spleen of treated animals (DS02) 
compared to vehicle controls, associated with lower levels of ERK1/2 phosphorylation in 
sorted CD45+/CD19+ splenic cells (Figure 4E, F).  
Next, we assessed the efficacy of Trametinib on the survival of two B-ALL+21 models 
carrying RAS activating mutations: iAMP01 (NRAS
G12V
) and HeH09 (KRAS
A146T
). Four 
weeks treatments with Trametinib decreased leukemia burden, associated with an 
increased survival compared to vehicles (Figures 5A-F). Importantly, similar results were 
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observed in two DS-ALL PDX models that harbor mutations in genes encoding upstream 
effectors of the RAS/MAPK pathway (Figures 5G-J).  
 
 Together, these results indicated that pharmacological inhibition of MEK1/2 
delayed disease development in murine models of B-ALL+21 presenting a constitutive 
activation of the RAS/MAPK pathway, irrespective of whether they carry genetic 
alterations affecting NRAS, KRAS, JAK2, and CBL genes. 
 
Trametinib synergizes with conventional chemotherapy in DS-ALL models 
To investigate the benefice of combining Trametinib with standard chemotherapy, dose-
response profile of B-ALL PDX blasts to Dexamethasone, Vincristine and Methotrexate 
treatments were defined in vitro. Most of our samples responded to Vincristine and 
Dexamethasone (Figure 6A and Supplementary Figures S7A, B). Next, we performed 
drug combinations studies using Dexamethasone, Vincristine, Methotrexate or Idarubicin 
in combination with Trametinib, and evaluated B-ALL blast viability by live cell 
imaging. Combination index calculation unveiled a synergy between Trametinib and 
Vincristine in both DS-ALL and HeH-ALL samples (Figure 6A, B and Supplementary 
Figures S7C) (34). A synergistic effect was also seen between Trametinib and 
Dexamethasone in all four DS-ALL models. 
Based on the synergy observed between Trametinib and Vincristine in vitro, efficacy of 
this combination was evaluated in two luciferase-expressing DS-ALL PDX models: 
DS02 (CRLF2/JAK2 positive) and DS06 (KRAS positive). Treatment was initiated after 




 in total flux 
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(ROI)), using 1.5 mg/kg/day of Trametinib, 0.5mg/kg of Vincristine (once per week), or 
both for 4 weeks. Trametinib alone significantly decreased leukemia burden at day 24 of 
treatment in both models (Figures 6C, F), confirming our previous observations. In 
survival analyses, we observed a decreased intensity in ROI between Vincristine alone 
and combo (Trametinib + Vincristine) group at the endpoint measurement for DS02 (day 
64, Figure 6D), and DS06 (day 205, Figure 6G) models, which was also associated with 
an increase in survival for both DS-ALL PDXs (Figures 6E, H). 
 
 Taken together, these preclinical studies showed that Trametinib combined with 
conventional chemotherapy, improved outcomes of DS-ALL PDX models presenting a 
constitutive of the RAS/MAPK pathway. 
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Discussion 
Children with Down Syndrome are predisposed to develop B-ALL and show an inferior 
prognosis compared to patients without DS due to a high risk of treatment-related 
morbidity and an increased rate of relapse (2, 3). In this study, we investigated the genetic 
landscape in DS-ALL and revealed that the oncogenic cooperation between constitutive 
trisomy 21 and RAS/MAPK pathway activation promotes cell proliferation, self-renewal 
and B-cell differentiation blockade associated with transcriptional alterations that can be 
modeled in murine cells. We also developed clinically-relevant models of human DS-
ALL, and other pediatric B-ALL+21 samples, to show that targeting the RAS/MAPK 
pathway, through MEK1/2 inhibition, in combination with currently used 
chemotherapeutic agents is a promising strategy to improve the outcome for these 
children. 
 
Constitutive RAS/MAPK pathway activation is a hallmark of cancer cells which in B-
ALL, can result either directly through somatic mutations affecting NRAS and KRAS 
genes or indirectly, through the alterations of upstream regulators, such as 
IL7R/CRLF2/JAK2 cytokine signaling or the FLT3 receptor tyrosine kinase axis (35). 
These results are in line with recent studies in DS-ALL (10, 11), and in other B-ALL+21 
samples (36-38). Interestingly, somatic gain of chromosome 21 is frequently seen in 
CRLF2-rearranged and BCR-ABL B-ALL (39-41), further highlighting the strong 
association between constitutive or acquired +21 and aberrant activation of signaling 
effectors. At the transcriptional level, we confirmed the low incidence of recurrent fusion 
transcripts leading to chimeric proteins in DS-ALL samples (11). Altogether, our cohort 
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is representative of the genetic, genomic and transcriptomic landscape of childhood B-
ALL+21, thus highlighting the suitability of our PDX models to better understand the 
mechanisms driving B cell leukemogenesis and test new pharmacological compounds. 
 
At the molecular level, Lane et al. showed that trisomy of the Hmgn1 gene, located in the 
DSCR, reactivates the expression of genes regulated by H3K27me3 to promotes B cell 
leukemogenesis; a phenotype conserved in human primary B-ALL+21 specimens (13). 
Here, our transcriptomic analyses suggested that KRAS
G12D
 B cell precursors are 
negatively enriched in datasets regulated by the PRC2 complex, thus antagonizing the 
effect of Hmgn1 trisomy, and emphasizing a molecular interplay between RAS/MAPK 
activation and H3K27 modifications, as seen in other tumor types (42, 43). Of 
importance, other genes of the DSCR may participate to leukemia development and/or 
maintenance in B-ALL+21, such as Dyrk1A shown to regulate B-cell proliferation and 
differentiation (18). To date, the chromosome 21 genes that functionally cooperates with 
RAS/MAPK pathway activation in human B cell leukemia remain elusive and will 
require further investigations. 
Here, we identified a transcriptional signature reflecting the cooperation between gain of 
chromosome 21 and RAS/MAPK pathway activation that is conserved in primary B-
ALL, and including overexpression LRRC32 and of USP36. LRRC32 encodes the pro-
tumorigenic Glycoprotein A Repetitions Predominant (GARP), known as critical 
regulator of latent TGFß activation and overexpressed in B cell malignancies (28, 29). 
The Ubiquitin Specific Peptidase USP36 has been shown to interact with FBW7 to 
regulate MYC stability (30) and enhance ERK and AKT signaling pathways (31). IRF4, a 
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key regulator of B cell differentiation, was also significantly downregulated in Ts1Rhr-
KRAS
G12D
 B cell precursors and in primary B-ALL+21 samples with constitutive RAS 





 B cells display a hyper-proliferative phenotype and are arrested at the pre-B stage 
(44). With regards to leukemogenesis, loss of Irf4 was also shown to facilitate BCR-ABL 
or Myc-induced B cell leukemia (45, 46), and we showed that decreased expression of 
IRF4 may also be implicated in DS-ALL samples with constitutive RAS/MAPK 
activation. These differential expressions in LRCC32, USP36 and IRF4 correlated with 
GSEA showing positive enrichments of TGFß signaling and MYC targets, and negative 
enrichments of late pre-B cells and BCR receptor signaling signatures. Thus, the Ts1Rhr-
KRAS
G12D
 model represents a useful tool to further characterize the underlying molecular 
mechanisms of oncogenic cooperation in DS-ALL. 
 
Given that DS children with B-ALL have a poor prognosis, targeting the molecular 
mechanisms underlying the proliferation of leukemic blasts could improve their outcome. 
Although CRLF2/JAK2 signaling is enhanced in half of DS-ALL and recent observations 
suggested that only high doses of the JAK1/JAK2 inhibitor, Ruxolitinib, decrease 
survival of leukemia cells (11), Jak2 was reported as dispensable for B-cell leukemia 
maintenance (47). The DS-ALL PDX models we developed in this study will allow us to 
assess the efficacy of Ruxolitinib treatment in future preclinical assays to establish the 
therapeutic benefit for DS-ALL harboring JAK2 activating mutations. Studies have 
recently shown that RAS mutations are associated with inferior prognosis in non-DS B-
ALL (48), that several subtypes of B cell leukemia carrying RAS mutations were 
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sensitive to MEK inhibition (49-51), and that Selumetinib synergized with 
dexamethasone to decrease viability of B-ALL cells (52). Here, we revealed that DS-
ALL are sensitive to Trametinib and further decrease leukemia burden and prolong 
survival in several PDX models when combined with Vincristine, regardless of the 
genetic alterations leading to RAS/MAPK pathway activation (RAS, JAK2 and CBL 
mutations). Overall, these results support the potential benefice of integrating Trametinib 
to conventional chemotherapies that include both Dexamethasone and Vincristine, to 
improve treatment efficacy of Down syndrome children with B-ALL.  
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Figure 1: Mutational landscape of B-cell Acute Lymphoblastic Leukemia with gain 
of chromosome 21 (B-ALL+21).  
A. Table summarizing selected somatic ‘driver’ alterations obtained from WES, RNAseq 
and MLPA/CGH assays in our B-ALL cohort: Down syndrome (DS-ALL, n=8), 
intrachromosomal amplification of the chromosome 21 (iAMP21, n=8), high 
hyperdiploid (HeH, n=16) and the `Others` subgroup (n=12), see also Supplemental 
Table 1.  Grey boxes represent the presence of a somatic alteration and the symbols 
specify the type of alteration (SNVs, gains, losses, Indels or rearrangements). The colored 
boxes (red, green, blue, yellow and orange) integrate all alterations found within the 
functional subgroups: signaling, transcription, chromatin, cell cycle and others.  
 
Figure 2: Functional cooperation between constitutive trisomy 21 and KRAS
G12D
. 
A. Number of CFU-preB colonies obtained per genotype (wild-type: WT and Ts1Rhr: 
Ts1) transduced with retroviral particles encoding KRAS
G12D
 or empty vector across four 
passages (n=8-10 replicates from 3 independent experiments; *p<0.05, **p<0.01 and 
***p<0.001). B. Representative picture of the CFU-preB colonies observed at passage 1 




 (scale bars, 0.2 mm). C. Western blot 





 cells. Quantifications of the band relative intensities are indicated. D. 





 murine B cell progenitors CFU-preB (132 
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Upregulated and 129 downregulated genes), n= 3 replicates per condition. E. Gene set 
enrichment analyses (GSEA) of selected enriched datasets; all FDR < 0.1, see also 
Supplemental Figure 4 and Table 6. F. GSEA of the 238 upregulated and 43 
downregulated genes across subgroups of human B-ALL contained in our cohort: Others, 
+21 (gain of chromosome 21, no RAS alterations) and +21RAS (gain of chromosome 21 
with N/KRAS mutations). G. Venn diagram assessing the association of the 238 
upregulated genes among the murine paired comparisons Ts1 vs WT, KRAS
G12D
 vs WT, 
Ts1+KRAS
G12D




. The same analysis was 
performed with the 43 downregulated genes, leading to the identification of 18 
`cooperative` genes (see Supplemental Table 7). H. Normalized expression of five 





, upper panel) and in human primary B-ALL samples 
(lower panel). *p<0.05 and **p<0.001. I. Growth of sorted GFP-positive Ts1+KRAS
G12D
 
ectopically expressing IRF4 compared to empty vector (MIE). **p<0.001. J. 
Representative dot plots (left panel) and associated bar graphs (right panel, n=3) showing 
acquisition of CD25 surface marker in IRF4-overexpressing Ts1+KRAS
G12D
 cells (at 
48h). **p<0.001. 
 
Figure 3: Establishment of a comprehensive cohort of PDX B-ALL+21. 
A-C. Left panel Representative flow cytometry analyses of the phenotypes of primary 
DS-ALL samples (DS01, DS02 and DS06) at diagnosis based on CD34, CD38, TSLPR 
and CD19 surface markers expression, and corresponding phenotypes from initial to 
NSG4 (right panel). D. Transcriptome correlation between primary DS01, DS02 and 
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DS06 samples (Y-axis) and their corresponding PDXs (X-axis); r = Pearson correlation 
coefficient. E. GSEA assessing the enrichment of the 238 upregulated and 43 
downregulated genes in B-ALL PDXs. F. Constitutive ERK1/2-phosphorylation assessed 
by Western blot of freshly harvested B-ALL PDX blasts starved overnight prior to 
protein extraction.  
 
Figure 4: RAS/MAPK pathway inhibition decreases viability of B-ALL cells in vitro 
and leukemia burden in vivo. 
A. Table comparing the IC50 values (µM) of Selumetinib (Selu) and Trametinib (Tra) in 
Ts1Rhr-KRAS
G12D
 cells and in four different B-ALL+21 PDX cells with constitutive 
RAS/MAPK pathway activation. B. Representative western blots assessing the efficacy 
of Selumetinib and Trametinib on ERK1/2 phosphorylation (P-ERK) on HeH02 PDX 
cells after 6h of treatment in vitro. C. Averaged IC50 values obtained in Others (n=5), 
DS-ALL (n=4) and HeH (n=7) PDX samples. *p=0.05. Regression curves used to 
calculate these IC50 values from several NSG recipients are represented in Supplemental 
Figure 6D. D. Histogram plots representing the percentage of Annexin-V positive DS02 
and iAMP01 cells at 48h. E. Absolute number of human CD45-positive cells detected by 
flow cytometry in the bone marrow (left panel) and spleen (right panel) of DS02 
recipient mice, at the end of a 4 weeks treatment with Trametinib (Tra, 1.5mg/kg, oral 
gavage). *p=0.05. F. Effect of Trametinib on ERK1/2 phosphorylation assessed by 
Western blot in flow sorted CD45/CD19 human DS02 cells at the end of the 4-weeks in 
vivo treatment (left panel); Intensities were normalized using HSC70 and ERK total 
protein (right panel). ****p<0.0001. 
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Figure 5: Trametinib treatment decreases leukemia progression in vivo. 
A. Left panel: Whole-body bioluminescence images after 4 weeks of treatment of 
iAMP01 PDX model. Right Panel: Absolute quantification of ROI 
(photons/second/surface [p/s/cm
2
]) between both groups (n=5 mice per group). 
**p=0.008. B. Proportion of human CD45+CD19+ cells in the peripheral blood at the end 
of treatment (average percentages ± SD are indicated). C. Survival curves of the iAMP01 
PDX model treated with vehicle (black) or Trametinib (1.5 mg/kg, green), (n=5 mice per 
group), **p=0.003. D-F. Efficacy of Trametinib in the HeH09 PDX model (n=5 mice per 
group), **p=0.0008 (in D), **p=0.002 (in F). G-H. Efficacy of Trametinib in the DS02 
model (n=4 mice per group), *p=0.04. (in H). I-J. Efficacy of Trametinib in the DS01 
model (n=6-9 mice per group), *p=0.04 (in I), ***p=0.0003 (in J). 
 
Figure 6: Trametinib synergizes with Vincristine to increase survival of DS-ALL 
PDX. 
A. Left panel: Dose-response curves of single agent treatment for Vincristine (Vc, blue), 
Dexamethasone (Dx, purple) and Methotrexate (Met, red) on DS02 PDX cells for 72h; 
Right panel: Dose-response curves assessing the combination of Vincristine with 
Trametinib (Tra) at 2 doses: 1 nM (brown) and 5 nM (orange), compared to Vc and Tra 
alone. B. Drug combination studies of Trametinib with Dexamethasone, Vincristine, 
Methotrexate and Idarubicin performed on DS-ALL (n=3-4 PDX) and HeH (n=2-3 
PDX). Combination indices (CI) were calculated according to (34) and represented in the 
right panel with CI<1 = synergy and CI>1 = antagonism. C and F. Left panels: 
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Representative whole-body bioluminescence images of luciferase-positive DS02 and 
DS06 PDXs at the end of the treatment with Trametinib (1.5 mg/kg) and/or Vincristine 
(0.5mg/kg). Right panels: Absolute quantification of bioluminescence in ROI 
(photons/second/surface [p/s/cm
2
]) during the last week of treatment (Day 24), *p<0.05; 
**p<0.01.  D and G. End point measurement of ROI in DS02 (D, day 64) and DS06 (G, 
day 205). E and H. Survival curves obtained for DS02 (E) and DS06 (G) PDXs (n=5 to 
7 mice per arm). *p<0.05; **p<0.01. 
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Figure 3 
IC50 (µM) Selu Tra 
Ts1Rhr-KRASG12D 0.06 0.0003 
DS01 (CBLmut) 1.02 0.02 
DS06 (KRASmut) 0.13 0.003 
HeH01 (NRASmut) 4.90 1.47 
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Figure 6 
